Targeted therapies have revolutionized cancer care, but the development of resistance remains a challenge in the clinic. To identify rational targets for combination strategies, we used an established melanoma mouse model and selected for resistant tumors following genetic suppression of NRAS expression. Complete tumor regression was observed in all mice, but 40% of tumors recurred. Analysis of resistant tumors showed that the most common mechanism of resistance was overexpression and activation of receptor tyrosine kinases (RTKs). Interestingly, the most commonly overexpressed RTK was Met and inhibition of Met overcame NRAS resistance in this context. Analysis of NRAS mutant human melanoma cells showed enhanced efficacy of cytotoxicity with combined RTK and mitogen-activated protein kinase kinase inhibition. In this study, we establish the importance of adaptive RTK signaling in the escape of NRAS mutant melanoma from inhibition of RAS and provide the rationale for combined blockade of RAS and RTK signaling in this context. Melanoma Res 27:545-557
Introduction
Metastatic melanoma is well known for its aggressive clinical behavior and resistance to both conventional and targeted therapies. Key mutations in the mitogenactivated protein kinase (MAPK) pathway have been identified in this disease including gain-of-function alterations in BRAF, which are present in ∼ 50% of all cutaneous melanomas [1] . Single-agent BRAF kinase inhibitors such as vemurafenib and dabrafenib are associated with impressive, but mostly short-lived regression of disease in BRAF-mutant melanomas [2, 3] . More recently, cotargeting BRAF and mitogen-activated protein kinase kinase (MEK) enhanced clinical response rates and progression-free survival compared with treatment with a BRAF inhibitor alone [4] [5] [6] [7] , leading to Food and Drug Administration approval of this combination in 2015. The future of targeted therapy for BRAF-mutant melanoma lies in the development of novel combination strategies that negate mechanisms of acquired resistance resulting from target-based therapies.
NRAS is mutated in 15-20% of melanomas, but efforts to pharmacologically inhibit mutant RAS directly have been unsuccessful to date [8] . RAS signals to several downstream effectors including phosphatidyl-inositol-3-kinase (PI3K)/AKT, RAL, and the RAF serine/threonine protein kinases, which activate MEK and extracellular signal-regulated kinase (ERK). Highly specific inhibitors of MEK have been developed and investigated clinically for their therapeutic efficacy in treating advanced melanomas, including those harboring NRAS mutations [9, 10] . In a phase II clinical trial, binimetinib (MEK162) had a response rate of 20% in NRAS mutant melanoma, making it the first targeted therapy to show activity in this molecular subgroup. Despite this response, progressionfree survival was brief (median: 3.6 months) [9] , highlighting the need for identification of resistance mechanisms to direct future therapeutic strategies.
A powerful way to identify rational targets for combination strategies is to use an in-vivo genetic approach.
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We recently described the development of a novel mouse model of melanoma on the basis of the RCAS/ TVA retroviral vector system, which allows for tissuespecific and cell-specific targeted infection of mammalian cells through ectopic expression of the viral receptor [11, 12] . This system utilizes a viral vector, RCASBP(A), referred to hereafter as RCAS, derived from the avian leukosis virus. The receptor for RCAS is encoded by the TVA gene, which is normally expressed only in avian cells. Transgenic mice expressing TVA under the control of the dopachrome tautomerase (DCT) promoter were generated to allow specific targeting of melanocytes [13] .
The highest heritable risk for melanoma results from mutations in the cyclin-dependent kinase inhibitor 2A (CDKN2A) locus [14, 15] , which encodes p16/INK4a and p14/ARF (p19/Arf in mice). This locus is also lost or mutated in ∼ 40% of sporadic melanomas [16, 17] . p16 inhibits CDK4/6-mediated phosphorylation of the retinoblastoma protein, allowing for unregulated cell division [18] , whereas loss of p14 enhances ubiquitination and degradation of p53 by HDM2, leading to pervasive genetic instability and a higher risk of melanoma in individuals with germline CDKN2A mutations [19, 20] .
To model human melanoma, we generated Dct::TVA; Cdkn2a lox/lox mice and virally delivered NRAS Q61R and Cre-recombinase postnatally to somatic melanocytes expressing TVA. Tumors developed in two-thirds of the mice following a mean latency of only 7 weeks. In this model, tumors evolve from gene mutations in developmentally normal somatic cells in the context of an unaltered microenvironment and therefore closely mimic the human disease [12] . We have further expanded the utility of this model by engineering the viral vectors to enable regulation of gene expression postdelivery using the tetracycline (tet)-regulated system [21] [22] [23] .
Mouse models that enable regulated expression of oncogenes are especially useful for modeling the effects of targeted therapies because abrogation of oncogene expression mimics pharmacological inhibition of the target [11] . These models often develop resistance and elucidation of the mechanisms of resistance can inform therapeutic strategies. The aim of this study was to identify rational targets for combination therapy in mutant NRAS-driven melanoma. To achieve this goal, we expressed NRAS Q61R under the control of a tetresponsive element (TRE) and examined mechanisms of resistance to suppression of NRAS expression in vivo. Interestingly, the most common mechanism of resistance responsible for the continued growth of these tumors in the absence of mutant NRAS was overexpression and activation of receptor tyrosine kinases (RTKs). Analysis of NRAS mutant human melanoma cell lines showed that escape from MAPK inhibition can be overcome by suppression of RTK signaling. These data suggest that combined inhibition of RTK and MAPK signaling is a rational combination therapeutic strategy that may prevent the development of resistance or treat recurrent melanoma driven by mutant NRAS.
Methods

Mice and genotyping
Dct::TVA;Cdkn2a lox/lox mice and genotyping have been described [12] .
Drugs
AZD6244 and XL-184 were purchased from Selleck Chemical (Houston, Texas, USA). Trametinib was purchased from ChemieTek (Indianapolis, Indiana, USA).
Establishment of melanoma cell lines and culture conditions
Mouse melanoma cell lines were established following the dissection of primary tumors by physical disruption into single cells using scalpels and trypsin. Melanocyte/ melanoma cultures were maintained in 254 medium containing human melanocyte growth supplement (Invitrogen, Carlsbad, California, USA), 10% fetal bovine serum (FBS), and 50 μg/ml gentamicin at 37°C with 5% CO 2 . Human melanoma cell lines WM1361A, WM1361AR, WM1346, WM1366, M245, and M318 were maintained in RPMI-1640 with 5% FBS, at 37°C with 5% CO 2 . WM1361AR cells are resistant to the MEK inhibitor AZD6244 and were maintained in the presence of the drug. DF-1 cells were grown in Dulbecco's Modified Eagle's medium-high glucose supplemented with 10% FBS, 1 × penicillin/streptomycin and maintained at 39°C as described [12] .
Viral constructs
The retroviral vectors used in this study are replicationcompetent avian leukosis virus LTR, splice acceptor, and Bryan polymerase-containing vectors of envelope subgroup A [RCASBP(A)] or no splice acceptor [RCANBP(A)]. RCASBP(A)Tet-off and RCANBP(A) have been described.
To generate RCANBP(A)TRE-NRAS
Q61R
-IRES-Cre, TRE was isolated from pTRE2Hyg (Clontech, Mountain View, California, USA) by Nco I and Xho I restriction digestion and cloned in to pENTR-3C NRAS
-IRESCre digested with Nco I and Xho I [12] . The subsequent LR Clonase II (Invitrogen) reaction with the Gateway Destination vector RCANBP(A) [24] and pENTR-3C-TRE-NRAS
-IRES-Cre generated RCANBP(A)TRE-NRAS Q61R -IRES-Cre. The final vector was sequence verified.
Virus production
Virus infection was initiated by calcium phosphate transfection of plasmid DNA that contained the retroviral vector in the proviral form in DF-1 cells as described previously [12] .
Met copy number analysis DNA was extracted from formalin fixed paraffin-embedded (FFPE) tissue and cell lines using the QIAamp DNA Mini Kit (Qiagen, Frederick, Maryland, USA) and quantified using a NanoDrop Spectrophotometer (ThermoFisher, Waltham, Massachusetts, USA). Met copy number analysis was carried out in replicates of six on the ViiA 7 Real-Time PCR System using 20 ng of DNA, TaqMan Universal Master Mix (ThermoFisher), Met TaqMan copy number probes (intron 2, mm0734318CN; ThermoFisher), and Tfrc TaqMan Copy Number Reference probes (4458368; ThermoFisher). The results were analyzed according to the manufacturer's instructions, normalized against internal Tfrc control probes, and compared with tail genomic DNA and FFPE tissue from wild-type mice.
RNA interference
The production of the pLenti6/Block-iT M1, M2 (targeting Met), and Luc (targeting luciferase) lentiviruses has been described [25] . Mouse melanoma cells were seeded in six-well plates at a density of 5 × 10 4 cells/well. After the cells attached, 1 ml of filtered virus-containing medium was added in the presence of 8 μg/ml polybrene (Sigma, St. Louis, Missouri, USA) for 2 h at 37°C.
In-vivo infection
Infected DF-1 cells from a confluent culture in a 10 cm dish were trypsinized, pelleted, and resuspended in 50 μl PBS, and placed on ice. Newborn mice were injected subcutaneously with 10 μl of cells as described [12] . All mice were monitored for tumor development daily. Tumor size was evaluated by caliper measurements and tumor volume was calculated by length × width × depth.
Immunohistochemistry
Tumor samples were fixed in 10% neutral-buffered formalin and paraffin embedded. Sections of 4 μm were cut, deparaffinized in xylene, and rehydrated in a graded alcohol series. NRAS Q61R -HA expression was detected using an antibody to the hemagglutinin (HA) epitope (HA.11; Covance, Salt Lake City, Utah, USA) (1 : 1000). Detection of MAPK activation was performed using a 1 : 100 dilution of an antibody to phosphorylated Erk (P-Erk, 4370; CST, Danvers, Massachusetts, USA). Met expression was detected using a rabbit polyclonal primary antibody to a peptide mapping within a C-terminal cytoplasmic domain of Met (Sc-162; Santa Cruz, Dallas, Texas, USA) diluted 1 : 200 in Renaissance diluent for 1 h at room temperature. Detection of Met phosphorylation was performed overnight at 4°C using a 1 : 100 dilution of a rabbit polyclonal antibody to phosphorylated (Y1003) Met (ab61024; Abcam, San Francisco, California, USA) in Renaissance diluent. The sections were washed with TBS-T and then probed with Mach 4 polymer reagent (Biocare, Pacheco, California, USA) for 30 min at room temperature. The signals were visualized with 3,3′-diaminobenzidine tetrahydrochloride (Biocare). Detection of Akt activation was performed using a 1 : 50 dilution in SignalStain 4060; CST). Visualization was performed using the Rabbit SignalStain Boost IHC Detection system and the SignalStain DAB Substrate Kit (CST). Cell proliferation was detected using an antibody diluted 1 : 50 to Ki67 (M7246; Dako). Apoptosis was detected by TdT-mediated dUTP nick end labeling (TUNEL) staining using the in-situ cell death detection kit (Roche, Indianapolis, Indiana, USA) according to the manufacturer's specifications. All sections were counterstained with hematoxylin.
Immunoblotting
Blots were immunostained using the following primary antibodies from CST: MET (8198), PMET (Y1234/5; 3077) as well as HA (HA.11; Covance), RAS10 (05-516, EMD Millipore, Billerica, Massachusetts, USA), and Tubulin (ab21058; Abcam). Detection was performed using anti-mouse or anti-rabbit IgG-HRP secondary antibodies as appropriate (CST). The blots were incubated in ECL solutions according to the manufacturer's specifications (Amersham, Piscataway, New Jersey, USA) and exposed to film.
Colony formation assay
Cells were plated in six-well plates at 2 × 10 4 per well. Media with vehicle [dimethyl sulfoxide (DMSO)] or 3 μmol/l XL-184 were added the following day and replaced twice a week. After 4 weeks, the plates were stained with crystal violet. Relative colony density was determined by solubilizing the crystal violet dye in 10% acetic acid, followed by measurement of absorbance at 450 nm.
Flow cytometry
Cells were treated with vehicle (DMSO), 1 μmol/l AZD6244, 3 μmol/l XL-184, 30 nmol/l trametinib or AZD6244 and XL-184, or trametinib and XL-184 in combination and harvested after 120 h. Cells were subsequently stained with Annexin-V/TMRM and apoptosis was assessed using an LSR-II flow cytometer. Results were analyzed with Flowjo (Flowjo, Ashland, Oregon, USA) and results representing the mean SEM from three independent experiments are shown.
Three-dimensional spheroid assays
Melanoma spheroids were prepared using the liquid overlay method. Spheroids were either treated for 144 h with vehicle control DMSO, 1 μmol/l AZD6244, 3 μmol/l XL-184, or AZD6244 and XL-184 in combination before being washed and analyzed as described previously [47] .
Reverse-phase protein array analysis
Frozen tumor tissue was embedded in an optimum cutting temperature compound. Hematoxylin and eosinstained slides were reviewed by an experienced dermatopathologist (A.J.L.) to identify areas that contained more than 70% tumor cells. Regions with extensive necrosis, fibrosis, or hemorrhage within the tumor specimens were excluded. The hematoxylin and eosin slides were used as a guide to macrodissect the optimum cutting temperature blocks and isolate tumor-enriched regions for further analysis. Tumor shears of 10-20 μm were generated by a cryostat and were used for protein and total RNA extraction. Proteins were isolated from the tumor shears and reverse-phase protein array (RPPA) was performed as described previously [26] .
Illumina gene-expression analysis
Microarray expression profiling was performed by the Microarray Core Facility of The University of Texas Health Science Center at Houston (Houston, Texas, USA). The RNA was amplified into cRNA and biotinylated by in-vitro transcription using the Illumina TotalPrep RNA Amplification Kit (Ambion, Austin, Texas, USA) according to the manufacturer's instructions. Biotinylated cRNAs were purified, fragmented, and subsequently hybridized to an Illumina Mouse-8 V2 BeadChip (Illumina, San Diego, California, USA). All analyses were carried out using GenomeStudio software (Illumina). The gene-expression data described in this manuscript have been deposited in the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/ ) database and are accessible through GEO Series accession number GSE51906.
Statistical analysis
Censored survival data were analyzed using a log-rank test of the Kaplan-Meier estimate of survival. For colony formation assays, each cell line was assayed according to the n indicated and the data are represented as the mean SEM. Quantitative analysis of TUNEL-positive and Ki67-positive cells was performed using ImageJ (NIH, Bethesda, Maryland, USA) and the data are represented as mean SEM. Student's t-test was used to determine significance. Student's t-test was also used to compare protein expression levels between groups in the RPPA analysis. Protein-protein coefficients were determined using the Pearson correlation method and the significance of the interactions was determined by the t-statistic using R software (R Foundation, Vienna, Austria). Unsupervised hierarchical clustering of meancentered protein expression values was performed using Clustal 2.1 (University College Dublin, Dublin, Ireland) and Treeview software (Free Software Foundation, Boston, Massachusetts, USA).
Study approval
All animal experimentation was conducted in AAALAC approved facilities at the University of Utah. All animal use protocols were reviewed and approved before experimentation by the Institutional Animal Care and Use Committee at the University of Utah. To allow for the regulation of NRAS expression postdelivery using the tet-regulated system, we utilized the RCANBP(A) vector, referred hereafter to as RCAN, that enables the use of an internal promoter [24] . A TRE promoter was inserted upstream of the NRAS Q61R -IRESCre cassette into the RCAN vector such that expression of both NRAS and Cre was driven from the TRE and not the viral long-terminal repeat. Delivering mutant NRAS and Cre into the same virus and linking their expression with an IRES ensured that all tumors developed in the context of mutant NRAS. We have shown previously that tumors do not form by the delivery of either mutant NRAS or Cre viruses alone in this model [12] . Expression from the TRE requires the presence of a tettranscriptional activator such as Tet-off. In the context of Tet-off, the Tet-responsive genes are repressed in the presence of doxycycline (Dox). Expression and activity of both NRAS and Cre were confirmed in vitro in the context of Tet-off before in-vivo experiments (data not shown).
Results
Delivery of viruses containing
We have previously shown that the expression of NRAS Q61R -IRES-Cre from these retroviruses efficiently induces melanoma in Dct::TVA;Cdkn2a lox/lox mice [12] . Tumors developed at the site of injection in 72% of the Dct::TVA;Cdkn2a lox/lox mice infected with both Tet-off and TRE-NRAS Q61R -IRES-Cre viruses (n = 46), whereas no tumors developed in Dct::TVA-negative;Cdkn2a lox/lox mice. Importantly, Dct::TVA;Cdkn2a lox/lox mice infected with viruses containing TRE-NRAS Q61R -IRES-Cre or Tet-off alone remained tumor free for the duration of the study (n = 20). The median overall survival of Dct::TVA; Cdkn2a lox/lox mice injected subcutaneously with viruses encoding Tet-off and TRE-NRAS Q61R IRES-Cre was 42.5 4.3 days (Fig. 1 ). Animals were euthanised because of primary tumor burden. Cell lines established from the primary melanomas expressed virally delivered mutant NRAS. As expected, administration of Dox to the culture medium resulted in loss of mutant NRAS expression. Importantly, the expression of endogenous Ras was not affected by Dox treatment (Fig. 1, inset) .
Tumors induced by the expression of Tet-off and TRE-NRAS Q61R -IRES-Cre were indistinguishable from tumors induced by the delivery of NRAS Q61R and Cre where expression was driven from the viral long-terminal repeat [12] . Macroscopically, the tumors were highly vascular and amelanotic as a result of the albino FVB/n background. Microscopically, high-grade nuclear features were observed along with prominent nucleoli and numerous mitotic figures. The tumors consisted primarily of short spindle cells, although some possessed giant cells with epithelioid features (Fig. 2a) . A HA epitope tag was engineered on the N-terminus of NRAS Q61R to allow for the distinction between virally delivered NRAS Q61R and endogenous NRas. Expression and activity of NRAS Q61R was verified by immunohistochemistry (IHC) for HA (Fig. 2b) and P-Erk (Fig. 2c) .
Suppression of NRAS expression promotes tumor regression and significantly increases survival
To determine whether downregulation of NRAS expression in Tet-off and TRE-NRAS Q61R -IRES-Creinitiated melanomas results in tumor regression, tumors were induced in Dct::TVA;Cdkn2a lox/lox mice by codelivery of viruses containing Tet-off and TRE-NRAS Q61R -IRESCre at birth. When tumors reached 1000 mm 3 , mice were assigned randomly to receive standard feed (untreated) or Dox-containing food to suppress NRAS Q61R expression. In the Dox-treated cohort, tumors progressed for 2-3 days after initiating treatment, followed by rapid tumor regression in all animals ( Supplementary Fig. S1 , Supplemental digital content 1, http://links.lww.com/MR/ A10). To evaluate the kinetics of virally delivered NRAS Q61R expression and activity following Dox treatment, we treated tumor-bearing mice with Dox for 24 or 72 h. Reduced expression and activity of NRAS Q61R was detected by IHC for HA and P-Erk following 24 h of Dox treatment (Fig. 2d-f) , and by 72 h of Dox treatment, NRAS Q61R and P-Erk expression were undetectable by IHC (Fig. 2g-i ). This correlates with the continued tumor growth observed in the Dox-treated mice 24-48 h following Dox administration and rapid tumor regression beginning at 72 h after the start of Dox treatment ( Supplementary Fig. S1 , Supplemental digital content 1, http://links.lww.com/MR/A10). As the tumors from all Doxtreated mice regressed, TUNEL assays were performed to quantify apoptotic cells. A significant difference in the mean number of TUNEL-positive cells was observed between the tumors from mice treated with Dox for 72 h [123 25.3/high-power field (HPF)] and untreated animals (45.6 9.98/HPF; P = 0.047) (Fig. 2j and k) . A significant difference was also observed between the two groups in the mean number of cells staining positively for the proliferation marker Ki67. Although 303 16.3 Ki67-positive cells were detected per HPF in the untreated tumor samples, 150 10.2 Ki67-positive cells were detected per HPF in the samples treated with Dox for 72 h (P = 0.004) (Fig. 2l and m) . These data suggest that tumor regression resulted from increased apoptosis as well as decreased proliferation.
Survival rates were compared between control mice (n = 38) and mice administered Dox (n = 25) using a logrank test of the Kaplan-Meier estimate of survival. Administration of Dox, and subsequent loss of NRAS Q61R expression, significantly increased survival. The median survival for control mice was 35.5 2.1 versus 137.5 15.1 days (P = 2.5 × 10 − 14 ) for Dox-treated mice that developed resistance. Complete responses were observed in 60% (15/25) of the treated mice (Fig. 3) .
Resistant tumors develop after a long latency in the absence of NRAS Q61R expression
Forty-percent (10/25) of the Dox-treated mice became resistant while on Dox treatment after a median latency of 61.5 11.3 days from the start of treatment ( Supplementary Fig. S1 , Supplemental digital content 1, http://links.lww.com/MR/A10). To delineate the mechanism(s) of resistance responsible for mediating tumor recurrence, we first evaluated all tumor tissue for expression of virally delivered NRAS Q61R . IHC for NRAS Q61R (HA) showed that 4/10 tumors re-expressed NRAS Q61R ( Supplementary Fig. S2 , Supplemental digital content 2, http://links.lww.com/MR/A11). Cell lines were established successfully from two of these tumors and in-vitro examination confirmed the expression of virally delivered NRAS even in the presence of higher concentrations of Dox ( Supplementary Fig. S3 , Supplemental digital content 3, http://links.lww.com/MR/ A12). Virally delivered NRAS Q61R expression was not . Inset: Tumor cells were derived from a mouse injected with viruses containing Tet-off and TRE-NRAS Q61R -IRES-Cre. The tumor cells were grown in the absence (− ) or presence (+) of 4 μg/ml doxycycline for 1 week. Forty-eight hours before lysis, the cells were maintained in media containing 10% serum (10%) or incubated in serumfree medium (SFM). Lysates were separated on a 16% Trisglycine polyacrylamide gel, transferred to nitrocellulose, and probed with an antibody directed against RAS. The membrane was reprobed with an antibody against α-tubulin to ensure equal loading. The RAS blot shows endogenous Ras (lower band) and the virally delivered NRAS Q61R (upper band). The virally delivered NRAS Q61R is a higher molecular weight as a result of the HA epitope tag.
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Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved. observed in the other six resistant tumors. Therefore, these tumors were further evaluated for activation of the canonical MAPK pathway by IHC for P-Erk. In contrast to the four tumors that retained NRAS Q61R -HA expression, MAPK pathway activation was not evident in the remaining six resistant tumors ( Supplementary Fig. S2 , Supplemental digital content 2, http://links.lww.com/MR/ A11).
PI3K/Akt pathway activation is a characteristic of the resistant tumors
To further define the signaling molecules active in the resistant tumors, we used unbiased RPPA, which enables quantitative analysis of protein expression and activation [27] . Tumor-enriched protein isolates from seven resistant tumor samples and three controls not subjected to NRAS extinction were analyzed by RPPA. The tumor samples were separated into 'NRAS on' and 'NRAS off' groups on the basis of the levels of virally delivered mutant NRAS expression in each tumor. The heat map in Fig. 4 shows the results of unsupervised hierarchical clustering of the proteins that showed a significant difference in expression (n = 29; P < 0.05 by an unpaired t-test) between the NRAS on and NRAS off samples. Importantly, activation of several RTKs was observed using this approach including ErbB1 (EGFR, Y1068) and ErbB2 (HER2, Y1248) as well as increased levels of VEGFR2. Interestingly, higher expression of several phosphoproteins (AKT, PRAS40, GSK3α/β) in the PI3K/ Akt pathway was observed in the NRAS off tumors, suggesting that increased activation of this pathway is a characteristic of the resistant tumors (Fig. 4) . Phosphorylated-Akt was also confirmed in several resistant tumors by IHC ( Supplementary Fig. S4 , Supplemental digital content 4, http://links.lww.com/MR/ A13).
Genetic suppression of NRAS in vivo increases the expression of receptor tyrosine kinases
To further characterize the mechanisms of resistance to genetic extinction of NRAS, we carried out geneexpression microarray analysis on eight tumor samples, including six resistant tumors and two untreated tumors. Analysis of the most highly upregulated genes in the resistant samples relative to untreated controls showed significant increases in the expression of several RTKs including c-Met, Fgfr1, Egfr, and Igfr1. Increased expression of Met appeared to be a common mechanism in three resistant tumor samples. Furthermore, the levels of Met expression were significantly different in these samples compared with the other tumors analyzed ( Supplementary Fig. S5 , Supplemental digital content 5, http://links.lww.com/MR/A14). Therefore, we further assessed Met expression in all of the tumor samples by IHC. Increased Met protein was observed in four of the 10 resistant tumors ( Supplementary Fig. 6A -J, Supplemental digital content 6, http://links.lww.com/MR/ A15). Met activity was confirmed in all of these samples by IHC for phosphorylated Met (Y1003) and a representative image for sample 3194 is shown in Supplementary Fig. 6K (Supplemental digital content 6, http://links.lww.com/MR/A15). Akt activity was also observed in this sample by IHC for phosphorylated Akt (P-Akt; S473) ( Supplementary Fig. 6L , Supplemental digital content 6, http://links.lww.com/MR/A15). To assess whether copy number alterations were responsible for the increase in Met expression in these tumors, we used TaqMan Copy Number Assays. Using this approach, we observed that the tumors with increased Met protein expression and the cell lines created from them contained highly significant increases in Met DNA copy number compared with untreated tumors and normal genomic controls (Fig. 5a and b) . Two of the resistant tumors (2908, 3194) contained over 30 copies of Met DNA. This increase in Met copy number was similar to what we have reported previously in DNA from melanoma xenografts (305, 303) [25] .
Inhibition of Met overcomes NRAS resistance generated in vivo
To evaluate a role for Met in mediating resistance, Metdirected M1 and M2 lentiviral shRNAs were delivered to the 2908 resistant tumor cell line in vitro. Significantly reduced Met expression and activity was confirmed in these cells by Western blot (Fig. 5c) . The requirement for Met expression in the escape from NRAS inhibition and Cre expression (n = 25, dashed line), whereas a separate cohort of tumor-bearing mice received standard feed (n = 38, solid line). Censored survival data were analyzed using a log-rank test of the Kaplan-Meier estimate of survival; P = 2.5 × 10 − 14 .
Resistance mechanisms in NRAS melanoma Robinson et al. 551 was shown by the ability of Met knockdown to prevent the outgrowth of clones in a 4-week colony formation assay (Fig. 5d) . Similarly, it was noted that XL-184, which has anti-Met activity, also significantly prevented the growth of the resistant cell lines, 2908 and 3267, which have increased Met expression and activity. XL-184 less efficiently inhibited cell line 3019, which retained mutant NRAS expression and does not have increased Met activity (Fig. 5e ).
Escape from MEK inhibition can be overcome through suppression of RTK signaling
Most patients with NRAS mutant melanoma who initially respond to MEK inhibition generally relapse [9] . Therefore, we next sought to determine whether coabrogation of RTK signaling prevented escape from MEK inhibition in human cells. The importance of adaptive RTK signaling in the escape from MEK inhibition was shown by the ability of the combination of either AZD6244 or trametinib with XL-184 to enhance human melanoma cell cytotoxicity in a 3D spheroid assay (Fig. 6a) , increase levels of apoptosis in an Annexin-V binding flow cytometry assay (Fig. 6b) , and prevent the outgrowth of clones in a 4-week colony formation assay in human melanoma cell lines ( Fig. 6c and Supplementary  Fig. S7 , Supplemental digital content 7, http://links.lww. com/MR/A16). We further validated our findings in the MEK inhibitor-resistant, NRAS mutated patient-derived cell line WM1361AR. Combination treatment with AZD6244 and XL-184 significantly reduced colony formation in these cells (Fig. 6c) .
Discussion
Significant progress has recently been made because of the development of targeted therapies for melanoma, particularly for those tumors that harbor activating BRAF V600E mutations [2] [3] [4] [5] . Attention has now turned to other genetic subgroups of melanoma, with clinical trials showing the potential utility of targeting the MEK/ERK signaling pathway in NRAS mutant melanoma [8, 9, 28] . Despite initially encouraging results, the duration of response to MEK inhibitors in this setting is limited, with treatment failure being rapid and resistance being almost universal. Thus, it is becoming increasingly clear that intracellular signaling networks are highly dynamic and subject to adaptation, and that this inherent plasticity is critical in the escape from small molecule kinase inhibitors. In melanoma, this phenomenon has been best Reverse-phase protein array analysis of protein from control and resistant melanomas. Protein was isolated from both untreated control tumors (noted by *) and NRAS-resistant tumors; expression was assessed by reverse-phase protein array. Log2 expression data were subjected to unsupervised clustering and the results are presented as a heat map. Tumors were labeled NRAS on (purple squares) or NRAS off (gray squares) on the basis of the expression of virally delivered mutant NRAS in the tumor samples. The heat map shown represents the proteins with P < 0.05 in t-tests between the NRAS on (n = 7) and NRAS off (n = 6) tumors. Green indicates decreased levels and red indicates increased levels. studied in the context of mutant BRAF, where signaling from RTKs provides important parallel signals that allow BRAF inhibition to be circumvented [29, 30] . Although this adaptive signaling has been little explored in NRAS mutant melanoma, an extensive understanding of these cellular processes will likely prove critical for the development of effective combination therapy strategies [8, 28, 31] . Resistance mechanisms in NRAS melanoma Robinson et al. 553 In the current study, we used an in-vivo mouse model of oncogene escape in which NRAS mutant melanomas were allowed to establish, regressed following genetic suppression of NRAS expression, and later developed resistance. The generation of oncogene resistance using a genetic approach in a spontaneous model of NRAS (1 μmol/l), XL-184 (3 μmol/l) or the two drugs in combination for 4 weeks. Colonies were visualized following staining with crystal violet. The relative colony density was determined by solubilizing the crystal violet dye in 10% acetic acid, followed by measurement of absorbance at 450 nm. The relative clonogenic survival (%)compared with the control is shown. **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
mutant melanoma offers a number of major advantages. Most importantly, this model provides a means to precisely determine whether inactivation of NRAS is an effective treatment for melanoma, with specific inhibition of oncogenic NRAS signaling accomplished in vivo and in the context of a normal microenvironment and intact immune system. In cases where responses are not durable, this model enables further study of the mechanisms of resistance that develop in vivo. We observed that targeting mutant NRAS caused significant tumor regression, showing that continuous NRAS signaling is required for tumor maintenance and progression while implicating the inhibition of mutant NRAS as a therapeutic target. Despite decades of research, specific pharmacological inhibition of NRAS has been unsuccessful to date, and efforts to extinguish oncogenic NRAS signaling continue [8] . Genetic suppression of NRAS Q61R in our model was not sufficient to prevent tumor recurrence as resistant tumors developed after a long latency in the absence of mutant NRAS. Analysis of these NRAS-resistant murine melanoma specimens showed re-activation of mutant NRAS in 40% of the samples and increased RTK expression in the remaining 60% of resistant tumors. The most commonly altered RTK was c-Met. We previously reported that increased c-Met gene copy number in the context of Ink4a/Arf loss is sufficient to drive melanomas in vivo [25] . Accordingly, we carried out an analysis of c-Met gene copy number in our resistant tumors and found that the increased c-Met expression corresponded with copy number alterations.
Met is an RTK whose expression is frequently increased in many tumor types, including melanoma [32] [33] [34] . Constitutive Met signaling, which often occurs following the establishment of an autocrine signaling loop through its ligand hepatocyte growth factor (HGF), promotes the growth and metastatic behavior of cancer cells through the activation of multiple signaling pathways including PI3K/AKT, MAPK, and Wnt [35] . For instance, Met functions as a melanoma oncogene in transgenic mice that are wild type for both BRaf and NRas by initiating a Met/Hgf autocrine loop [36] . In melanoma patient specimens, increased MET expression has been implicated in tumor progression, with receptor expression correlating with melanoma growth and metastasis [37, 38] . Recent studies have shown that concomitant overexpression of transcription factors ETS1, PAX3, and SOX10 that drive upregulation of Met in melanoma cell lines and primary tumors [34, 39] . Here, we report that increased Met expression mediates the generation of NRAS-resistant melanoma in vivo, whereas inhibition of Met overcomes this resistance, indicating that combination strategies that suppress RTK signaling with the MAPK pathway inhibition may be therapeutically beneficial.
There is already evidence from epithelial cancers that upregulated RTK signaling overcomes MAPK pathway inhibition. In colorectal carcinoma, escape from knockdown of KRAS is associated with increased AKT signaling mediated through IGF1R [40] . In this context, suppression of KRAS expression decreases the throughput of the MAPK signaling pathway, leading to the relief of feedback inhibition mediated through the adaptor protein IRS-1 [40] . Similar signaling adaptations have also been observed in triple-negative breast cancer, where inhibition of MEK leads to therapeutic escape associated with the increased expression and activity of a number of RTKs including HER2, RON, AXL, VEGF, and PDGFR-β [41] . In a similar manner, rewiring of the kinome has also been observed in melanoma cells treated with BRAF inhibitors, and it has been suggested that increased RTK signaling arising from both tumor intrinsic growth factor autocrine loops and host-derived factors is a key survival adaptation [29, 42, 43] . Of these, increased ERBB3 signaling, secondary to an enhanced expression of the transcription factor, FOXD3, has been implicated in short-term tumor-intrinsic adaptive resistance [42] . HGF released from host fibroblasts has also been shown to confer resistance to the BRAF inhibitor PLX4720, with levels of stromal HGF being found to correlate with innate resistance to BRAF inhibitor therapy [43] . More recently, HGF was shown to rescue both mutant NRAS and BRAF melanoma cell lines from the growth inhibitory effects of MAPK pathway inhibition [44] .
Additional studies have also implicated growth factors such as EGF, IGF1R, and PDGF in acquired BRAF inhibitor resistance [45] [46] [47] . Met activation in melanoma cell lines containing mutant BRAF has been shown to confer primary resistance to PLX4032 as well [45] . Most recently, a comprehensive transcriptome analysis of serial tumor biopsies from patients before and after mutant BRAF inhibitor therapies, including BRAF alone or combination with MEK inhibition, showed an increase in c-MET transcripts in resistant tumors [48] . This increased expression mediated MAPK inhibitor resistance. Furthermore, c-MET mRNA upregulation indicated poor survival prognosis [48] .
Melanoma cell lines and tumor specimens express a large number of cell surface growth factor receptors, all with the potential to mediate escape signaling. The exact complement of RTKs responsible for driving innate or acquired resistance to small molecule kinase inhibitors in melanoma remains to be determined and targeting these modalities remains a significant clinical challenge. Amuvatinib (MP-470), which inhibits MET, KIT, PDGFRA, and AXL, was shown to attenuate NRAS mutant melanoma cell growth and induce apoptosis in vitro [49] ; however, MP-470 has not been assessed clinically. The small molecule MET, RET, KIT, FLT-1, FLT-3, FLT-4, TIE2, AXL, and PDGFR-β kinase inhibitor XL-184 (cabozantinib) was assessed in a phase II randomized trial and induced tumor regression in 55% of melanoma patients (5% objective response rate), with no correlation noted between response and BRAF status [50] . We show that the addition of XL-184 to NRAS mutant human melanoma cells increased the cytotoxicity of the MEK inhibitors, AZD6244 and trametinib, as measured by 3D spheroid assays, apoptosis assays, and long-term colony formation assays. The observation that RTK inhibitors prevent escape from MEK inhibition in NRAS mutant melanoma is supported by preclinical studies of breast cancer, BRAF-mutant colorectal carcinoma, and KRAS mutant colon cancer showing that RTK inhibitors (including pan-RTK, EGFR/HER kinase, and IGF1R) enhance the antitumor activity of RAS/MEK/ ERK signaling ablation [40] [41] [42] .
In this study, we show for the first time the importance of adaptive RTK signaling in the escape of NRAS mutant melanoma from the inhibition of signaling through RAS in vivo. We propose that adaptive RTK signaling and copy number variations provide a selective survival advantage; resistant cells are then initially reliant on localized stromal signaling before undergoing clonal evolution for increased RTK copy number or further mutation, leading to independence from stromal signaling and recurrence. Our results provide additional rationale for the cotargeting of both RAS/MEK and RTK signaling.
